Drug Levels and Effects
Information in this record refers to the use of flutemetamol F 18 as a diagnostic agent. No information is available on the use of flutemetamol F 18 during breastfeeding. The manufacturer recommends withholding breastfeeding for 24 hours after a diagnostic dose of 185 MBq (5 mCi). This length of time is about 10 half-lives of fluoride F 18 and less than 0.01% of the radioactivity administered will remain in the body. The mother can nurse just before administration of the radiopharmaceutical. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[1][2][3]
Drug Levels
Fluoride F18 decays by positron emission with a physical half-life of 109.7 minutes.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
1 Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. http://www
2 Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. Nucl Med Commun. 1989;10:15-27. [PubMed]
3 Early PJ, Sodee DB. Principles and practice of nuclear medicine. 2nd ed. St. Louis. Mosby-Year Book, Inc. 1995:1380-1.
Substance Identification
Substance Name: Flutemetamol F 18
CAS Registry Number: 765922-62-1
Drug Class
-
Radiopharmaceuticals
-
Fluorine Radioisotopes
Print 
PDF